Clinical trials: Generalized Anxiety
Generalized Anxiety Disorder
A Study of Duloxetine in Elderly Generalized Anxiety Disorder
The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).
- Trial name
- NCT01118780
- Testing
- Duloxetine
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder.
- Trial name
- NCT06010654
- Testing
- Software as a Medical device
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- HAII corp.ltd
Generalized Anxiety Disorder
Pilot Study of Virtual Reality for Providing Exposure Therapy to Children
Drs. from the Mayo Clinic Rochester will plan and execute a feasibility study of the phase I prototype version of the Virtual Reality exposure therapy system. Dr.
- Trial name
- NCT03208348
- Testing
- Pilot Virtual Reality
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Generalized Anxiety Disorder
Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD
A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD
- Trial name
- BGFN-2022-02 (NCT06243640)
- Testing
- Buagafuran capsules, 15mg/ capsule, Buagafuran capsules mimic, 0mg/ capsule
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Generalized Anxiety Disorder, Panic Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and…
- Trial name
- NCT00266409
- Testing
- Niravam, SSRI/SNRI
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- UCB Pharma
Generalized Anxiety Disorder
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
- Trial name
- NCT00595231
- Testing
- SYN111
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Biotie Therapies Inc.
Generalized Anxiety Disorder
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
- Trial name
- NCT03829241
- Testing
- Troriluzole
- Where
- 53 sites in United States
- Volunteers
- 881 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Generalized Anxiety Disorder
Escitalopram in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the…
- Trial name
- NCT00902564
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Anxiety, Generalized Anxiety Disorder
Brain Stimulation & Generalized Anxiety Study
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
- Conditions
- Anxiety, Generalized Anxiety Disorder, Generalized Anxiety
- Trial name
- NCT04751864
- Testing
- Cranial Electrotherapy Stimulator (CES) Device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- ProofPilot